Scarica l'app Stockscreener
1.88
1.08%
0.02
Nervgen Pharma Corp Borsa (NGEN) Ultime notizie
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
NGEN Forecast — Price Target — Prediction for 2027 - TradingView
9UA Forecast — Price Target — Prediction for 2027 - TradingView
NervGen Pharma Corp. Actuals & Estimates (FWB:9UA) - TradingView
NervGen Pharma Corp. Actuals & Estimates (DUS:9UA) - TradingView
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Slight EPS Beat Highlights Disciplined Expense Management in Pre-Revenue StageFull Year Guidance - dars.gov.et
Spinal Cord Injury Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehab - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spinal Cord Injury Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Mitsubishi Tanabe Pharma America, Kringle Pharma - Barchart.com
Nervgen Pharma Ord Shs (NGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NervGen Pharma (NGEN) Slips 7.5% as Selling Pressure Mounts: Key Support Levels in FocusWMA Signal - dars.gov.et
NGEN Q3 2025 Earnings: Narrowed Loss Beat Estimates as Pipeline AdvancesSubscription Growth Report - dars.gov.et
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
How one School of Medicine researcher’s legacy offers hope for those with spinal cord injuries - Case Western Reserve University
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
NervGen Pharma Corp. Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In Phase 1b/2a CONNECT SCI Study - marketscreener.com
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):